Scientists of the KIT and the University of Kiev have produced an antibiotic, whose biological activity can be controlled with light.
Thanks to the robust diarylethene photoswitch, the antimicrobial effect of the peptide mimetic can be applied in a spatially and temporally specific manner. This might open up new options for the treatment of local infections, as side effects are reduced. The researchers present their photoactivable antibiotic with the new photomodule in a “Very Important Paper” of the journal “Angewandte Chemie”.
Photoswitchable molecules modify their structure and properties when exposed to light of an adequate wavelength. Among the photoswitches known are diarylethenes. By reversible photoisomerization, i.e. a reversible light-induced internal relocation of the molecule, the open form is turned into a closed form. Such photoswitch-able molecules are applied in molecular electronics and many other areas. Particularly interesting opportunities result from the insertion of photoswitches into biomolecules to control their activity by light. Interest focuses on so-called peptide mimetics, compounds whose major structural elements emulate a peptide, i.e. a small protein.
For the first time now, a group of researchers headed by Professor Anne S. Ulrich, Director of the Institute for Biological Interfaces 2 (IBG2) and holder of the Chair for Biochemistry at the Institute of Organic Chemistry (IOC) of KIT, has produced a photoswitchable peptide mimetic based on a diarylethene scaffold that can be photoisomerized reversibly. The scientists modified this building block into an amino acid analog and incorporated it directly into the backbone of the annular peptide antibiotic Gramicidin S. Biological activity of the resulting peptide mimetic can be controlled spatially and temporally with the help of UV and visible light. To demonstrate this, the scientists treated a bacterial film with the inactivated antibiotic and exposed it to light via a mask. As a result, the photoswitchable diarylethene was converted from a closed into an open form. Due to the structural modification induced, the entire substance molecule had a much higher antimicrobial effect. “In the future, such photoactivable antibiotics might be used as smart therapeutic agents against local bacterial infections,” Professor Anne S. Ulrich explains. “Usual side effects can also be minimized by switching.” Based on this strategy, new peptide-based agents against cancer might be feasible, as the newly developed photoactivable building block can also be applied in other peptide sequences.
The Latest on: Antibiotic
via Google News
The Latest on: Antibiotic
- Common antibiotic found useful in accelerating recovery in tuberculosis patientson June 18, 2021 at 9:00 pm
Researchers from NUS Yong Loo Lin School of Medicine's Infectious Diseases Translational Research Programme have discovered that the use of a common antibiotic, doxycycline, in combination with TB ...
- New antibiotic to combat deadly bacterial 'superbugs' enters clinical trialson June 18, 2021 at 7:04 am
In a critical step toward addressing an urgent unmet medical need due to infections caused by antibiotic-resistant bacteria—also known as superbugs—a new antibiotic (QPX9003) discovered by Monash ...
- Old Antibiotic Novobiocin Inhibits Growth of BRCA-Mutated, PARPi-Resistant Tumors in Miceon June 18, 2021 at 5:00 am
Investigators aim to start clinical trial of novobiocin in patients with tumors that have relevant genetic alterations.
- Fish oil supplements could combat antibiotic resistanceon June 18, 2021 at 4:00 am
Fish oil supplements may break down "superbugs" that have become resistant to antibiotics, research suggests. The World Health Organization has called antibiotic resistance "one of the biggest threats ...
- Man Contracts 'Antibiotic-Resistant' Flesh-Eating Bacteria After Using Roommate's Razoron June 18, 2021 at 3:50 am
After using his roommate's razor, a 24-year-old from Los Angeles developed bumps that resembled spider bites and wouldn't respond to antibiotics.
- Scientists unshelve a decades-old antibiotic to fight a new foe — ovarian canceron June 17, 2021 at 8:09 am
The results are preliminary, but convincing enough that researchers are moving ahead with a Phase 1 clinical trial in ovarian cancer.
- Antibiotic Novobiocin found to kill tumor cells with DNA-repair glitchon June 17, 2021 at 8:00 am
An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute ...
- Urbanization drives antibiotic resistance on microplastics in Chinese riveron June 16, 2021 at 8:05 am
Microplastic pollution of waterways has become a huge concern, with the tiny pieces of plastic entering food webs and potentially having harmful effects on animals and people. In addition, ...
- Trained viruses prove more effective at fighting antibiotic resistanceon June 7, 2021 at 12:52 pm
The threat of antibiotic resistance rises as bacteria continue to evolve to foil even the most powerful modern drug treatments. By 2050, antibiotic resistant-bacteria threaten to claim more than 10 ...
via Bing News